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ABSTRACT
The relationship between oral and general health has been increasingly recognised during the past two
decades. Several epidemiological studies have linked poor oral health with cardiovascular disease, poor
glycaemic control in diabetics, low birth-weight pre-term babies, and a number of other conditions,
including rheumatoid arthritis and osteoporosis. Oral infections are also recognised as a problem for
individuals suffering from a range of chronic conditions, including cancer and infection with human
immunodeﬁciency virus, as well as patients with ventilator-associated pneumonia. This review
considers the systemic consequences of odontogenic infections and the possible mechanisms by which
oral infection and inﬂammation can contribute to cardiovascular disease, as well as the oral conditions
associated with medically compromised patients. A large number of clinical studies have established the
clinical efﬁcacy of topical antimicrobial agents, e.g., chlorhexidine and triclosan, in the prevention and
control of oral disease, especially gingivitis and dental plaque. The possible risks of antimicrobial
resistance are a concern, and the beneﬁts of long-term use of triclosan require further evaluation. Oral
infections have become an increasingly common risk-factor for systemic disease, which clinicians should
take into account. Clinicians should increase their knowledge of oral diseases, and dentists must
strengthen their understanding of general medicine, in order to avoid unnecessary risks for infection
that originate in the mouth.
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INTRODUCTION
Advances in the understanding, prevention and
treatment of oral diseases during the past
50 years have led to a signiﬁcant increase in
the number of individuals retaining more of
their natural teeth for longer periods of time.
However, many of these teeth have been heavily
restored and are prone to further breakdown,
and this increasingly dentate population is at
risk for periodontal disease. The goal of modern
dental care is oral health, but this cannot always
be achieved or maintained. Often, only an arrest
of disease progression can be attained, and
chronic asymptomatic infections may persist. In
addition, chronic or malignant diseases of the
mucosa are increasingly common. The mouth has
thus become a signiﬁcant potential source of both
infection and inﬂammation that contributes to the
total burden of disease and to overall health and
well-being.
The oral microbiota is both rich and unique.
A similar microbiota does not exist elsewhere.
In healthy individuals, viridans group strepto-
cocci constitute the majority of the indigenous
oral ﬂora. However, the most common bacteria
isolated from pus samples from odotontogenic
infections are facultative anaerobic streptococci
and anaerobic Gram-negative bacilli, e.g., Prevo-
tellae and Fusobacterium spp. [1,2]. Currently, a
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signiﬁcant proportion of Prevotellae isolates
worldwide are b-lactamase producers, and
b-lactam antibiotics alone are thus ineffective
against these organisms. For this reason, metro-
nidazole has been used in combination with
penicillin in order to achieve improved efﬁcacy
against anaerobes.
Actinobacillus (now Aggregatibacter) actinomyce-
temcomitans and Porphyromonas gingivalis are also
key oral pathogens and have frequently been
associated with periodontal diseases. It is also
interesting to note that both of these organisms
can invade oral epithelial cells, which contributes
to their immune evasion and resistance to anti-
biotic treatment [3,4]. Actinomyces spp. are part of
the normal oral microbiota and constitute the bulk
of the structural elements of the dental plaque
bioﬁlm. These organisms are also found in cases
of peri-implantitis, which is an infection of dental
implant supporting tissues, and which may result
in loss of the implant [5]. In addition, they can
cause actinomycosis of jaws. Candida albicans is
the most common yeast found in the oral cavity,
although the proportion of non-albicans Candida
isolates has increased in recent years, especially in
patients with fragile health.
ODONTOGENIC INFECTIONS
The spread of oral infections is generally conﬁned
by anatomical barriers or tissue planes, e.g.,
muscle and bone. However, spread of infection
back and down to the larynx and the media-
stinum can occur [1]. A central principle is that
oral infections cannot be resolved merely by use
of antibiotics, and successful treatment is always
based on properly conducted dental procedures.
Nevertheless, antibiotic treatment is important
and, as stated above, a combination of penicillin
and metronidazole should be considered. An
odontogenic infection can spread very rapidly,
and the airway may become obstructed within a
few hours. If this occurs, rapid intubation or
tracheostomy and intensive care may be required.
An example of a life-threatening infection origi-
nating in the mouth is Lemierre’s syndrome,
which is a rare septic condition that usually
requires intensive care. Isolation of Fusobacterium
necrophorum is common, and a suppurative
thrombophlebitis in the vena jugularis interna
and metastatic abscesses in the lungs or the brain
can develop [1].
The mouth clearly represents an important
reservoir of microorganisms and any infection
caused by these organisms should alert the clini-
cian to the possibility of an oral source [6–8].
While there have been a number of reports of
brain abscess being caused by oral microorgan-
isms [9], the classical example is endocarditis
caused by viridans group streptococci. According
to the infectious diseases register of the Finnish
National Public Health Institute (http://www.
ktl-ﬁn/tartuntatautirekisteri), the number of adult
septicaemias caused by viridans streptococci
has almost doubled in the past 10 years, which
is directly proportional to the number of indivi-
duals remaining dentate throughout their lives.
Viridans group streptococci are currently the ﬁfth
most common cause of septicaemia among adults
in Finland.
In this context, it is therefore important for
infectious disease physicians to give increasing
attention to oral health. The possibility of an oral
source should be considered for any infection of
unknown origin. Oral infections often remain
asymptomatic, and may still result in bacteraemia
despite an absence of overt symptoms. Minor oral
procedures, including brushing of teeth, as well
as invasive dental procedures, e.g., removal of
dental calculus, root treatment and surgery, may
all result in bacteraemia, even in an otherwise
healthy individual [10,11]. Furthermore, an oral
infection may provide the physician with clues for
diagnosis of a systemic disease. For example, oral
candidosis, in the absence of any other explana-
tion, could suggest infection with human immu-
nodeﬁciency virus at a stage when the CD4+ cell
count is still high and the disease is still otherwise
asymptomatic.
THE MEDICALLY COMPROMISED
PATIENT
An increasing number of systemic diseases, e.g.,
gastroenterological and rheumatological, are trea-
ted with moderate-to-severe immunosuppressive
agents. Malignancies, with their associated ther-
apies, also affect an increasingly large proportion
of the population. The oral health of medically
and immunologically compromised patients is
fundamental to the overall care of these patients.
Oral infections are typically chronic and often
present with minor symptoms; however, they
remain controlled while the immune defences
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and tissue responses of the patient remain intact.
In a susceptible immunocompromised patient,
even an asymptomatic, chronic osteitis or a mild
Candida mucositis (Fig. 1) can become a source of
life-threatening generalised infection [12,13]. It is
therefore important to ensure that all foci of oral
infection are eliminated whenever possible before
commencing treatment. This is also important
before cardiac surgery or the placement of joint
prostheses [14]. Imaging of the teeth and tooth-
supporting bone and jaws should be the minimum
routine (Fig. 2). A thorough clinical examination
by a dentist experienced in oral medicine is also
highly recommended.
Poor oral health (Fig. 3) and extensive stoma-
titis, responsible for signiﬁcant morbidity, are
common in patients receiving cancer therapies
[15–18]. Oral mucosal lesions may provide a
portal of entry for systemic infection that may
prevent or delay the continuation of cancer
treatment [19–21], thereby having a signiﬁcant
effect on the ﬁnal prognosis (including mortality),
and a major impact on the costs of care [22].
Regular removal of bacterial plaque from tooth
surfaces is important in order to keep the micro-
bial load and challenge to a minimum during
cancer treatments [23,24]. In this context, tooth-
brushing alone may be insufﬁcient or impossible
to carry out because of pain, and the use of
antimicrobial toothpastes and mouthwashes may
be necessary [17,25]. When the mucosa is dam-
aged, brushing may lead to substantial bactera-
emia, and the use of an antimicrobial mouthwash
is therefore recommended before or instead of
brushing. Several reports have demonstrated that
a chlorhexidine mouthwash is effective in con-
trolling both the oral infection per se and the
consequences of any bacteraemia [17,25]. Careful
mechanical (brushing and ﬂossing) or chemical
(antimicrobial mouthwashes) oral hygiene should
always be a part of cancer therapy. Barker et al.
[22] highlighted considerable variation among
centres in their understanding and appreciation
of the signiﬁcance of oral health in medically
compromised patients; they concluded that an
increase in oral complications has evolvedwith the
development of cancer therapies, and that medico-
dental collaboration is therefore important.
Osteomyelitis of the jaw is a rather uncommon
infection, with diabetes and haemodialysis
being known risk-factors [1]. However, there is
Fig. 1. The mouth of a patient with severe stomatitis
caused by chronic candidosis. The patient was diagnosed
with an autoimmune disease against adrenal and parathy-
roid glands.
Fig. 2. An orthopantomogram of a male aged 36 years
who was suffering from dental fear. The whole dentition is
severely damaged, and the remaining roots are foci for
chronic and acute osteitis.
Fig. 3. The mouth of a male aged 58 years with severely
damaged dentition and periodontitis.
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increasing evidence of osteonecrosis of the
mandible being associated with high-dose or
long-lasting bisphosphonate therapy. Bisphosph-
onates, which are pyrophosphate analogues, are
strong osteoclast inhibitors that are used in the
treatment of osteoporosis and solid tumours with
bony metastasis. The safe optimal dose and
duration of treatment should be evaluated and
the subset of patients at increased risk for
osteonecrosis should be identiﬁed, as the necrosis
seems to be irreversible and the treatment of these
patients is very difﬁcult [26].
Actinomycosis of the cervicofacial region,
caused primarily by any of several members of
the bacterial genus Actinomyces, is another rare
infection, usually presenting as a mass adjacent to
the mandible, which may penetrate the surround-
ing bone and muscle and form a ﬁstula to the
skin. Carious teeth, dental manipulations and
maxillo-facial trauma are known sources of infec-
tion [1,27]. The pathogenesis is related to the
ability of these organisms to act as intracellular
parasites and thus resist phagocytosis. Actino-
mycosis has a tendency to spread without respect
for established tissue planes or anatomical barri-
ers, and this can sometimes be confused with
malignancy.
SIGNIFICANCE OF ORAL
INFECTIONS IN THE
DEVELOPMENT OF SYSTEMIC
DISEASES
The importance of the role of infection and
inﬂammation in the initiation and progression of
the endothelial damage in atherosclerosis is now
widely accepted [28–30]. Chronic inﬂammatory
periodontal diseases are found worldwide and
are among the most prevalent chronic infec-
tions in humans. Individuals with severe chronic
periodontitis have been reported to have a sig-
niﬁcantly increased risk of developing cardio-
vascular disease, including atherosclerosis,
myocardial infarction and stroke, even after
adjusting for many of the traditional risk-factors
[31–33].
Since the early work carried out in Finland
[28–34], there have been >50 studies investigating
the relationship between periodontal and cardio-
vascular disease, with the majority showing a
signiﬁcant, albeit modest, positive association,
even after adjusting for confounders. However,
while epidemiological studies indicate associa-
tions, they do not establish causality. Care must
be taken in interpreting these cross-sectional
epidemiological studies and, as emphasised by
Hujoel et al. [35], studies of longitudinal interven-
tion and pathogenic mechanisms are urgently
required. A number of short-term studies exam-
ining the effect of periodontal treatment on the
surrogate markers of cardiovascular disease have
been performed [36–38]. In general, these studies
show that periodontal treatment results in a
signiﬁcant reduction in such markers of cardio-
vascular disease, e.g., interleukin-6 and C-reactive
protein. These changes are also accompanied by
an improvement in endothelial function and
arterial elasticity.
Possible biological mechanisms linking perio-
dontal and cardiovascular disease include
molecular mimicry between the bacterial heat-
shock protein GroEL and human heat-shock
protein 60 (hHSP60). This hypothesis, ﬁrst sug-
gested by Wick et al. [39,40], involves cross-
reactivity between the immune response mounted
against a bacterial infection and hHSP60
expressed on stressed or damaged endothelial
cells. Yamazaki et al. [41] have shown that T-cells
reactive with both GroEL and hHSP60 have
identical nucleotide sequences in their T-cell
receptor b-chain genes, and that such T-cells exist
both in the atherosclerotic plaques themselves
and in the periodontal tissues. Cross-reactive
T-cells have also been shown to be present in
the peripheral blood of patients with atheroscle-
rosis [42,43], and antibodies to GroEL cross-react
with hHSP60, and vice versa. In addition, P. gin-
givalis has been shown to enhance the develop-
ment of atherosclerosis in an animal model, and
this enhancement is associated with increased
levels of anti-GroEL antibody [43].
Other possible mechanisms linking periodontal
and cardiovascular disease include direct infec-
tion of the blood vessel walls by periodontal
organisms. Leukocytes do not adhere to healthy
endothelium, but if the endothelium is damaged,
e.g., by direct infection, the endothelial cells will
express adhesion molecules to which white blood
cells adhere. Monocytes adhere and migrate into
the intima, where they phagocytose the oxidised
low-density lipids that form the so-called foam
cells. The foam cells then release matrix metallo-
proteinases that degrade extracellular matrix
components in the vessel wall, resulting in
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atherosclerosis [44]. These cholesterol plaques
that form at the site of injury can rupture,
increasing the likelihood of myocardial infarction
or stroke. An interesting ﬁnding is that the known
matrix metalloproteinase inhibitor tetracycline is
as effective as periodontal treatment in lowering
the level of C-reactive protein in coronary heart
disease patients with periodontitis [44]. Extensive
studies have shown that systemic diseases, e.g.,
diabetes and cardiovascular disease, and perio-
dontitis share links between biomarkers of
systemic inﬂammation (C-reactive protein, inter-
leukin-6, tumour necrosis factor-a, matrix metallo-
proteinase-9).
These pathogenic mechanisms are not mutually
exclusive, but clearly establish the role of infection
in the pathogenesis of atherosclerosis. Despite the
lack of deﬁnitive long-term intervention studies,
the importance of preventing and treating infec-
tions, especially chronic infections such as peri-
odontitis, should become paramount in terms of
the advice and treatment given to patients with
coronary heart disease.
PREVENTION OF ORAL INFECTIONS
Oral infection continues to be a major public
health problem worldwide. Good oral hygiene is
essential for good oral health, and the routine
control of dental plaque is fundamental. How-
ever, the widespread prevalence of oral disease
indicates the inability of most individuals to
achieve a level of plaque control consistent with
good oral health. Approaches aimed at improving
the oral hygiene of the population have therefore
included the addition of antibacterial agents to
oral care products. While chlorhexidene is con-
sidered to be the reference standard, it has
signiﬁcant side-effects that limit its widespread
long-term use.
Triclosan is an alternative antimicrobial agent
with a broad spectrum of activity against oral
microorganisms. This agent is more suitable for
long-term use, as it does not have signiﬁcant side-
effects and, importantly, it has a long history of
safe use in consumer products. Its dual antimi-
crobial and anti-inﬂammatory properties offer
advantages in the management of periodontal
diseases and oral mucosal conditions, and there
are now numerous studies demonstrating its
effectiveness in reducing plaque and gingivitis
[45]. Triclosan has also been shown to slow the
progression of periodontal disease over a 3–5-year
period in adults and adolescents with pre-existing
disease [46–48]. It is expected that these beneﬁts
will compound with continued use over even
longer periods of time [47]. This could have a
signiﬁcant impact on disease expression in the
population at large. The consequences of long-
term use of any antimicrobial agent are a concern,
and the therapeutic advantages have to be
weighed against the possibility of reduced sus-
ceptibility and the emergence of resistant strains.
To date, there is no evidence that triclosan
formulations for oral use will select for triclosan-
resistant strains [49,50], but there are well-docu-
mented therapeutic beneﬁts. It is interesting to
note that the major therapeutic beneﬁt, in terms of
chronic periodontitis, is seen in susceptible
patients or those with pre-existing disease. Med-
ically and immunologically compromised pa-
tients represent a susceptible population, such
that it would be reasonable to expect that triclo-
san-containing toothpastes would be of value in
the control of oral infection in these patients.
However, this remains to be shown, and further
studies are necessary to determine the effect
of these products in medically compromised
patients.
CONCLUSIONS
The number of individuals retaining more of their
natural teeth for longer periods of time has
increased during the past few decades. Adequate
oral hygiene is difﬁcult to achieve, and chronic
asymptomatic infections of teeth, their supporting
tissues and oral mucosa are common. Mainte-
nance of oral health is a special challenge for
medically compromised patients or those with
acute illness. The mouth is a signiﬁcant potential
source of infection and inﬂammation that con-
tributes to the total burden of disease, and to
overall health, which should be systematically
taken into account by all clinicians.
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